Leo Pharma hits the speeder as the company now plans to shower the market with new treatments for both rare and more common skin diseases.
This is at the core of the pharmaceutical company’s recently announced strategy, which will function as a guideline for the company up until 2030 and position the company for launching new pharmaceutical drugs every second year, if everything goes according to plan.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
GN purchase story is very speculative, says analyst
Competition rules could block a purchase of GN Store Nord and subsequent divestment of GN Hearing, says a Sydbank analyst on the speculative story that this might be underway.
Novo Nordisk invests additional millions of dollars in new manufacturing facilities
Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.
CHMP to remove 100 generic medicines from market
Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.
Germany orders 40,000 monkeypox vaccines from Bavarian Nordic
The German Minister for Health has revealed that the German state has ordered vaccines from Bavarian Nordic, as the country reports 5 cases of monkeypox.
New head of research at Astellas Gene Therapies: "Choosing the right indications is extra important"
Morten Søgaard is leaving Pfizer to join Astellas, where he will be in charge of 100 employees. Going from one of the world largest pharmaceutical firms to a considerably smaller one will be a challenge, he says.
Clinical Trial Administrator 
Clinical Project Manager 
Key Account Manager, Europe and Asia 
Analytical Coordinator for Analytical Development 
(Senior) Drug Substance Specialist 
IRT Manager, Clinical Drug Supply 
Strategic Procurement Manager, Direct Spend (Category Manager) 
Project Manager & Scrum Master 
System Sales Development Consultant - Investment Projects, Merck Millipore 
Clinical Trial Manager for development of in vitro diagnostics 
Director Global Engineering 
Scientific Writer 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
Nordic Medical Affairs Manager 
Director for innovative pre-clinical testing unit 
Production Director 
Senior Chemical Safety Advisor 
Laboratory technician for process development and clinical manufacturing 
Account Manager